Sustained Reductions In Red Blood Cell (Rbc) Transfusion Burden And Events In Beta-Thalassemia With Luspatercept: Longitudinal Results Of The Believe Trial

Introduction: β-thalassemia is a genetic blood disorder characterized by ineffective erythropoiesis and anemia. Although RBC transfusions are a key supportive treatment for patients (pts) with anemia due to β-thalassemia, they may be associated with life-threatening complications including iron overload. Luspatercept, a first-in-class erythroid maturation agent, is approved by the FDA for the treatment of anemia in adult pts with β-thalassemia requiring regular RBC transfusions.